Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 2/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16379394 | 1.00 | KMT2A (0.64) | KMT2AEPHX2DPP8DPP7TLR2 | |
| SCHEMBL12972620 | 0.92 | KMT2A (0.63) | KMT2AEPHX2DPP8DPP7TLR2 | |
| SCHEMBL30887302 | 0.92 | KMT2A (0.63) | KMT2AEPHX2DPP8DPP7TLR2 | |
| SCHEMBL15160784 | 0.92 | KMT2A (0.63) | KMT2AEPHX2DPP8DPP7TLR2 | |
| SCHEMBL14682729 | 0.92 | KMT2A (0.63) | KMT2AEPHX2DPP8DPP7TLR2 | |
| Hydrochloric Acid SCHEMBL29398229 | 0.91 | KMT2A (0.61) | KMT2AEPHX2DPP8DPP7TLR2 | |
| SCHEMBL2089280 | 0.91 | KMT2A (0.67) | KMT2AEPHX2DPP8DPP7CASP3 | |
| SCHEMBL18924161 | 0.91 | KMT2A (0.64) | KMT2AEPHX2DPP8DPP7TLR2 | |
| SCHEMBL29401202 | 0.91 | KMT2A (0.67) | KMT2AEPHX2DPP8DPP7CASP3 | |
| SCHEMBL29398504 | 0.91 | KMT2A (0.67) | KMT2AEPHX2DPP8DPP7CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9284283-B2 | Macrocyclic compounds for modulating IL-17 | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2016-03-15 | — | — | US | disclosed |
| US-20150005319-A1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | ENSEMBLE THERAPEUTICS CORPORATION | 2015-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005319-A1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | IL17A, IL15, IL2 | KMT2A 3399/4885EPHX2 1747/4885DPP8 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.